217.99
0.07%
-0.16
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$218.15
Offen:
$219.63
24-Stunden-Volumen:
328.99K
Marktkapitalisierung:
$32.00B
Einnahmen:
$4.58B
Nettoeinkommen (Verlust:
$958.38M
KGV:
35.39
EPS:
6.16
Netto-Cashflow:
$1.07B
1W Leistung:
-0.03%
1M Leistung:
+17.18%
6M Leistung:
+42.66%
1J Leistung:
-7.94%
Resmed Inc. Stock (RMD) Company Profile
Firmenname
Resmed Inc.
Sektor
Telefon
858-836-5000
Adresse
9001 Spectrum Center Boulevard, San Diego, CA
Resmed Inc. Stock (RMD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2023-09-06 | Hochstufung | Needham | Hold → Buy |
2023-09-05 | Herabstufung | UBS | Buy → Neutral |
2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2023-05-23 | Eingeleitet | UBS | Buy |
2023-04-14 | Eingeleitet | Mizuho | Buy |
2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
2022-10-12 | Eingeleitet | Jefferies | Hold |
2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
2021-08-02 | Herabstufung | Needham | Buy → Hold |
2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
2021-06-21 | Bestätigt | Needham | Buy |
2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
2021-03-16 | Hochstufung | Needham | Hold → Buy |
2020-11-02 | Hochstufung | UBS | Neutral → Buy |
2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-02-03 | Eingeleitet | CLSA | Underperform |
2020-01-31 | Herabstufung | UBS | Buy → Neutral |
2020-01-10 | Eingeleitet | Oppenheimer | Perform |
2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
2019-07-29 | Hochstufung | UBS | Neutral → Buy |
2019-07-16 | Herabstufung | UBS | Buy → Neutral |
2019-05-06 | Hochstufung | UBS | Neutral → Buy |
2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc. Aktie (RMD) Neueste Nachrichten
Hologic's (HOLX) Q2 Earnings Beat Estimates, 2024 View Up
Zacks Investment Research
Lantheus (LNTH) Q1 Earnings Surpass Estimates, Gross Margin Up
Zacks Investment Research
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Decline
Zacks Investment Research
Teleflex (TFX) Q1 Earnings Beat Estimates, Margins Rise
Zacks Investment Research
4 Safe Bets Amid Growing Concerns Over Delay in Rate Cuts
Zacks Investment Research
Zimmer Biomet (ZBH) Q1 Earnings Beat, Margins Expand
Zacks Investment Research
Finanzdaten der Resmed Inc.-Aktie (RMD)
Resmed Inc. (RMD) Umsatz 2024
RMD meldete einen Umsatz der letzten 12 Monate von 4.58 Milliarden US-Dollar für das Quartal zum 2024-03-31, was einem Anstieg von +14.16% im Vergleich zum Vorjahr entspricht.
Resmed Inc. (RMD) Nettogewinn 2024
RMD betrug am 2024-03-31 der Nettogewinn der letzten 12 Monate 958.38 Millionen US-Dollar, was einem Anstieg von +11.06% im Vergleich zum Vorjahr entspricht.
Resmed Inc. (RMD) Free Cashflow 2024
RMD verzeichnete einen Free Cashflow der letzten 12 Monate von 1.07 Milliarden US-Dollar für das Quartal bis zum 2024-03-31, was einem Anstieg von +162.78% im Vergleich zum Vorjahr entspricht.
Resmed Inc. (RMD) Gewinn je Aktie 2024
Der Gewinn je Aktie (EPS) von RMD für die letzten 12 Monate betrug 6.51 US-Dollar für das Quartal, das am 2024-03-31 endete, was einem Wachstum von +10.90% im Vergleich zum Vorjahr entspricht.
Resmed Inc.-Aktie (RMD) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Drexler Karen | Director |
Apr 29 '24 |
Sale |
214.92 |
425 |
91,341 |
8,446 |
Rider Michael J | Global General Counsel |
Mar 04 '24 |
Sale |
180.00 |
81 |
14,580 |
6,607 |
Rider Michael J | Global General Counsel |
Mar 01 '24 |
Sale |
173.25 |
200 |
34,650 |
6,688 |
FARRELL PETER C | Director |
Feb 22 '24 |
Sale |
182.66 |
10,935 |
1,997,434 |
157,404 |
Sandercock Brett | Chief Financial Officer |
Nov 27 '23 |
Sale |
152.62 |
3,000 |
457,860 |
92,962 |
Farrell Michael J. | Chief Executive Officer |
Nov 15 '23 |
Option Exercise |
57.76 |
5,678 |
327,961 |
446,664 |
Farrell Michael J. | Chief Executive Officer |
Nov 15 '23 |
Sale |
152.04 |
5,678 |
863,281 |
440,986 |
Rider Michael J | Global General Counsel |
Nov 01 '23 |
Sale |
143.42 |
25 |
3,585 |
7,358 |
Farrell Michael J. | Chief Executive Officer |
Oct 16 '23 |
Option Exercise |
57.76 |
5,675 |
327,788 |
455,035 |
Farrell Michael J. | Chief Executive Officer |
Oct 16 '23 |
Sale |
140.70 |
5,675 |
798,464 |
449,360 |
Kapitalisierung:
|
Volumen (24h):